Старение. Профессиональный врачебный подход Верткин Аркадий

   38. Caughey G.E., Vitry A.I., Gilbert A.L., Roughead E.E. Prevalence of comorbidity of chronic diseases in Australia // BMC Public Health, 2008; 8:221

   39. Chaitman B.R., Pepine C.J., Parker J.O. et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial // JAMA. 2004. Vol. 291. № 3. P. 309–316.

   40. Chaitman B.R., Skettino S.L., Parker J.O. et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina // J. Amer. Coll. Cardiology. 2004. Vol. 43. № 8. P. 1375–1382.

   41. Chang К. Т., Min K.-T. Regulation of lifespan by histone deacetylase // Ageing Res. Rev. 2002. Vol. 1. P. 313–326.

   42. Charlson M.E., Pompei P., Ales H.L. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation // Journal Chronic Disease, 1987; 40:373–383

   43. Ciunmings D.E., Merriam С.R. Growth hormone therapy in adults // Annu. Rev. Mcd. 2003. Vol. 54. P. 513–533.

   44. Clark W.R. Reflections on an unsolved problem of biology: the evolution of senescence and death. Advances in Gerontology. 2004. Vol. 14. P. 7–20.

   45. Cloninger C.R. Implications of comorbidity for the classification of mental disorders: the need for a psychobiology of coherence // Psychiatric Diagnosis and Classification, 2002; p. 79–105

   46. Cohen-Mansfield J, Kivity Y. The relationships among health behaviors in older persons.

   47. Cuijpers P., van Lammeren P., Duzijn B. Relation between quality of life and chronic illnesses in elderly living in residential homes: a prospective study // Int Psychogeriatr, 1999; 11: 445–454

   48. Cullen W., O’Brien S., O’Carroll A., O’Kelly F.D., Bury G. Chronic illness and multimorbidity among problem drug users: a comparative cross sectional pilot study in primary care. BMC Fam Pract. 2009 Apr 21;10:25.

   49. Dasgupta S. A computer simulation for biological aging J. de physique. 1994. Vol. 4. P. 1563–1570.

   50. Daveluy C., Pica L., Audet N. Enqute Sociale et de Sant 1998. 2nd ed. Qubec: Institut de la statistique du Qubec ; 2001

   51. DCCT Research Group Reliability and validity of a diabetes quality of life measure for the diabetes control and complications trial (DCCT) // Diabetes Care, 1998; 11:725–732

   52. De Boer J., van der Horsi G., Т., Hoeijmakers J.H. Mutant mice as a model of human diseases of aging. Defective transcription and premature aging // Tijdscr Gerontol. Ceriatr. 1999. Vol. 30. P. 168–170.

   53. de Groot V., Beckerman H., Lankhorst G.J., Bouter L.M. How to measure comorbidity: a critical review of available methods.J Clin Epidemiol. 2003 Mar;56(3):221-9.

   54. de Groot V., Beckerman H., Lankhorst G.J., Bouter L.M. How to measure comorbidity: a critical review of available methods // J. Clin Epidemiol, 2003; Mar;56(3):221-9

   55. Dean W., Biological Aging Measurement // Clinical Applications, 1986.397 р.

   56. Dean W. Biological aging measurement J. Gerontogeriatric s. 1998. Vol. 1. P. 4–5.

   57. Desai M.M., Bogardus S.T. Jr., Williams C.S., Vitagliano G., Inouye S.K. Development and validation of a risk-adjustment index for older patients: the high-risk diagnoses for the elderly scale // J Am Geriatr Soc. 2002; Mar; 50(3): 474-81

   58. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases // J Clin Epidemiol, 1992; Jun;45(6):613-9

   59. Diederichs C., Bartels D.B., Berger K. The Importance Of A Standardized Instrument To Assess The Burden Of Multimorbidity.J Gerontol A Biol Sci Med Sci. 2011 Sep 7

   60. Dozmorov I., Bartke A., Miller R. A. Array-based expression analysis of mouse liver genes: effect of age and of the longevity mutant Propldf J. Gerontol. A Biol. Sci. Med. Sci. 2001. Vol. 56. P. B72–B80.

   61. Dzerve V., Matisone D., Pozdnyakov Y., Oganov R. Mildronate improves the ex ercise tolerance in patients with stable angina: results of a long term clinical trial // Sem Cardiovasc Med. 2010; 16 (3): 1–8.

   62. Dzerve Vilnis, MILSS I Study Group. A Dose-Dependent Improvement in Exercise Tolerance in Patients With Stable Angina Treated With Mildronate: A Clinical Trial «MILSS I» // Medicina (Kaunas) 2011; 47 (10): 544–551.

   63. Edgar D., Shabalina I., Camara Y., Wredenberg A., Calvaruso M.A., Nijtmans L., Nedergaard J., Cannon B., Larsson N.G., Trifunovic A. Random point mutations with major effects on protein-coding genes are the driving force behind premature aging in mtDNA mutator mice // Cell Metab. 2009 Aug;10(2):131-8.

   64. Elshtein N. Polymorbidity in gastroenterological ractice. Acta Medico Baltica 1996; 1: 70-3.

   65. Evan G., Uttlewood T. A matter of life and cell death//Science. 1998. Vol.281. P. 1317–1322.

   66. Feinstein A.R. Pre-therapeutic class ification of co-morbidity in chronic disease // Journal Chronic Disease, 1970; 23(7):455–468

   67. Feudjo-Tepie M.A., Le Roux G., Beach K.J., Bennett D., Robinson N.J. Comorbidities of Idiopathic Thrombocytopenic Purpura: A Population-Based Study // Advances in Hematology, 2009.

   68. Fialova D., Onder G. Medication errors in elderly people: contributing factors and future perspectives.Br J Clin Pharmacol. 2009 Jun;67(6):641-5

   69. Findley P., Shen C., Sambamoorthi U. Multimorbidity and persistent depression among veterans with diabetes, heart disease, and hypertension.Health Soc Work. 2011 May;36(2):109-19.

   70. Fortin M., Bravo G., Hudon C., Vanasse A., Lapointe L. Prevalence of multimorbidity among adults seen in family practice // Ann Fam Med, 2005; 3: 223-8

   71. Fortin M., Dionne J., Pinho G., Gignac J., Almirall J., Lapointe L. Randomized clinical trials: Do they have external v alidity for patients with multiple comorbidities? // Ann Fam Med, 2006; 4:104-8

   72. Fortin M., Lapointe L., Hudon C., Vanasse A. Multimorbidity in medical literature: Is it commonly researched? // Can Fam Physician, 2005; 51:244–245.

   73. Fortin M., Lapointe L., Hudon C., Vanasse A. Multimorbidity in the medical literature: a bibliometric study // Can Fam Physician, 2004

   74. Freeman J.T. Aging: Its History and Literature. – N. Y.; L.: Human Sciences Press, 1979. 161 p.

   75. Frieling T. Age-related functional gastrointestinal disorders. Z Gastroenterol. 2011 Jan;49(1): 47–53.

   76. Fuchs Z., Blumstein T., Novikov I. Morbidity, comorbidity, and their association with disability among community-dwelling oldest in Israel // J Gerontol A Biol Sci Med Sci. 1998; 53A(6):M447-M455

   77. Gavrilova N.S., Gavrilov L.A. et al. Evolution, mutations, and human longevity: Euro pean royal and noble families // Human Biol. 1998. Vol. 70. P. 799–804.

   78. Gijsen R., Hoeymans N., Schellevis F.G., Ruwaard D., Satariano W.A. Causes and consequences of comorbidity: a review // Journal of Clinical Epidemiology, 2001; July. Vol. 54, issue 7, p. 661–674.

   79. Gill T., Feinstein A.R. A critical appraisal of the quality-of-life measurements // JAMA, 1994; 272: 619–626.

   80. Gladyshev G.P. Thermodynaniics theory of biological evolution and aging. Su-pramolecular thermodynamics is a key to understanding phenomena of life. What is life from a physical chemist’s viewpoint // Успехи геронтологии 2002. Т. 9. С. 49–53.

   81. Globerson A. R., Abel E.L., Ben-Menahem D. Developmental aspects of T-lym-phocytes in aging // Goldstein A. L., ed. Biornedical Advances in Aging. New York; London: Plenum Press, 1990. P. 363–373.

   82. Gompertz B. On the Nature of the Function Expressive of the Law of Human Mortality. Phil. Trans. Royal Soc. (London). 1825.

   83. Gonzalez-Suarez E., Samper E., Flores J.M., Blasco M.A. Teomerase-deficient mice with short telomeres are resistant to skin tomorigenesis. Nature Genet. 2000. Vol. 26. P. 114–117.

   84. Greenfield S., Apolone G. The importance of coexistent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement: Comorbidity and outcomes after hip replacement // Med Care, 1993; 31:141–154

   85. Grimby A., Svanborg A. Morbidity and health-related quality of life among ambulant elderly citizens // Aging, 1997; 9:356-364

   86. Grolla D.L., Tob T., Bombardierc C., Wright J.G. The development of a comorbidity index with physical function as the outcome // Journal of Clinical Epidemiology, 2005; June; volume 58, issue 6, p. 595–602.

   87. Hanaki Y., Sugiyama S., Ozaw a T. Effect of 3-(2,2,2-trimelhylhydrazinium) propionate, gamma-butyrobetaine hydroxylase inhibitor, on isoproterenol – induced mitochondrial dysfunction // Res. Commun. Chem. Phatol. Pharmacol. 1999; 64: 157–160.

   88. Harboun M., Ankri J. Comorbidity indexes: review of the literature and application to the elderly population // Rev Epidemiol Sante Publique, 2001; Jun;49(3):287–98.

   89. Harman D. Extending functional life span. Exp. Gerontol. 1998. Vol.33. P. 95–112.

   90. Hasty P., Camptsi J., Hoeijmakers J. et al. Aging and genome maintenance: lessons from the mouse? Science. 2003. Vol. 299. P. 1355–1359.

   91. Hayfiick L. How and why we age. Exp. Cerontol. 1998. Vol. 33. P. 639–653.

   92. Hayflick L., Moorhead P. S, The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961. Vol. 25. P. 585–621.

   93. Hayftick L. New approaches to old age. Nature. 2000. Vol. 403. P. 365.

   94. Hoffman C., Rice D., Sung H.Y. Persons with chronic conditions. Their prevalence and costs // JAMA, 1996; 13;276(18): 1473-9.

   95. Holden L., Scuffham P.A., Hilton M.F., Muspratt A, Ng S.K., Whiteford H.A. Patterns of multimorbidity in working Australians. Popul Health Metr. 2011 Jun 2;9(1): 15.

   96. Hunger M., Thorand B., Schunk M., Dring A., Menn P., Peters A., Holle R. Multimorbidity and health-related quality of life in the older population: results from the German KORA-age study.Health Qual Life Outcomes. 2011. Jul 18; 9: 53.

   97. Increased multimorbidity in patients in general practice in the period 2003–2009. Ned Tijdschr Geneeskd. 2011; 155(26): A3109. Dutch.

   98. Ingram D.C., Nakamura K., Smucny D. Strategy for identifying biomarkers of aging in long-lived species // Exp. Cerontol. 2001. Vol. 36. P. 1025–1034.

   99. Jak ovljevic M., Reiner Z., Milicic D., Crncevic Z. Comorbidity, multimorbidity and personalized psychosomatic medicine: epigenetics rolling on the horizon. Psychiatr Danub. 2010 Jun;22(2):184-9.

   100. Jazwinski S.M. Genetics of longevity. Exp. Gerontol. 1998. Vol. 33. P. 773–783.

   101. Jensen I. Proceedings: Pathology and prognostic factors in temporal lobe epilepsy. Follow-up after temporal lobe resection // Acta Neurochir, 1975; 31(3–4): 261-2.

   102. Jialal I., Devaraj S. Antioxidants and atherosclerosis. Don’t throw out the baby with the bath water. Circulation. 2003. Vol. 107. P. 926–928.

   103. Jlrich P., Ceratni A. Protein glycation, diabetes, and aging // Recent Progr. Horm. Res. 2001. Vol. 56. P. 1–21.

   104. Kaplan M.H., Feinstein A.R. The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus // Journal Chronic Disease, 1974; 27: 387–404, 1 974

   105. Kaplan M.H., Feinstein A.R. Acritique of methods in reported studies of long-term vascular complications in patients with diabetes mellitus // Diabetes, 1973; 22(3): 160-174

   106. Kipling D., Faragfter R. G. A. Ageing hard or hardly ageing? Nature. 1999. Vol, 398. P. 191–192.

   107. Kirk D. Demographic transition theory. Popul. Stud. 1996. Vol. 50. P. 361–387.

   108. Kirkwood T.B.L Evolution of ageing. Mech. Ageing Dev. 2002. Vol. 123. p. 737–745.

   109. Kishi S., Uchiyama J., Baughman A.M. et al. The zebrafish as a vertebrate model of functional aging and very gradual senescence // Exp. Getontol. 2003. Vol. 38. P. 777–786.

   110. Konhilas J.P., Leinwand L.A. Partnering up for cardiac hypertrophy // Circ Res 2006; 98 (8): 985–987 and Comment Circ Res 2006; 98 (8): 1089–1097.

   111. Korpelaii K. Human life histories and the demographic transition: A case study from Finland, 1870–1949. Am. J. Phys. Anthropol. 2003. Vol. 120. P. 384–390.

   112. Kowald A. Lifespan does not measure ageing // Biogerontology. 2001. Vol. 3. P. 187–190.

   113. Kraemer H.C. Statistical issues in assessing comorbidity // Stat Med, 1995; 14:721–723

   114. Krishnan E. Hyperuricemia and Incident Heart Failure // Circ Heart Fail 2009; 2: 556–62.

   115. Kruseman A.C., Mulder W.J., Pijpers E. Ageing and polymorbidity: is therea mismatch between the training of internists and the need? Neth J Med. 2007 Nov;65(10):363-5.

   116. Laine H., Katoh C., Luotolahti M. Myocardial oxygen consumption is unchanged but efficiency is reduced in patients with essential hypertension and left ventricular hypertrophy // Circulation 1999; 100: 2425-30.

   117. Lango R., Smolenski R.T., Narkiewicz M. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass // Cardiovasc. Res. 2001. Vol. 51, № 1. P. 21–29.

   118. Lee C.K., Klopp R.C, Weindruch R., Prolla T.A. Gene expression profile of aging and its retardation by caloric restriction // Science. 1999. Vol. 285. P. 1390–1393.

   119. Lee L., Horowitz J., Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment // Eur. Heart J. 2004. Vol. 25, № 8. P. 634–641.

   120 . Lee S.J., Lindquist K., Segal M.R., Covinsky K.E. Development and validation of a prognostic index for 4-year mortality in older adults // JAMA, 2006; Feb;15;295:801-8.

   121. Linn B.S., Linn M.W., Gurel L. Cumulative illness rating scale. J Amer Geriatr Soc // 1968; 16:622–626.

   122. Lio D., Mario Pes C., Carru С. et al. Association between the HLA DR alkies and longevity: a study in Sardinian population //Exp. Gerontol. 2003. Vol. 38. P. 313–318.

   123. Littdenberger U., Sikstrvm S. Aging cognition: from neuromodulation to representation Trends Cogn. Sci. 2001. Vol. 5. P. 479–486.

   124. Lopaschuk G.D., Wall S.R., Olley P.M. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chainacylcarnitine // Circ. Res. 1988. Vol. 63. № 6. P. 1036–1043.

   125. Lovell M. Caring for the elderly: Changing pe rceptions and attitudes. J. Vasc. Nurs. 2006. Vol. 24(1). Р. 22–26.

   126. Makeham W. M. On the Law of Mortality, and Construction of Annuity Tables. JIA, VIII. 1860.

   127. Makolkin V., Osadchiy K. Trimetazidine modified release in the treatment of stable angina. TRIUMPH Study // Clin. Drug Invest. 2004. Vol. 24, № 12. – P. 731–738.

   128. Marengoni A., Angleman S., Melis R., Mangialasche F., Karp A., Garmen A., Meinow B., Fratiglioni L. Aging with multimorbidity: A systematic review of the literature.

   129. Marian A. J. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy // Lancet, 2000. V. 355. P. 58–60.

   130. Martnez Velilla N. Multimorbidity: the ultimate geriatric syndrome. Rev Esp Geriatr Gerontol. 2010 Jul-Aug;45(4): 177-8. Epub 2010 May 12.

   131. Martnez Velilla N.I., Gaminde Inda I. Comorbidity and multi morbidity indexes in the elderly patients. Med Clin (Barc). 2011 Apr 16; 136(10):441–6

   132. Mathur R., Hull S. A., Badrick E., Robson J. Cardiovascular multimorbidity: the effect of ethnicity on prevalence and risk factor management.Br J Gen Pract. 2011 May; 61(586): P. 262–70.

   133. Matsumoto A. M., Marck В.Т., Gruenewald D.A. Aging and the neuroen-docrine regulation and body weight//Exp. Gerontol. 2000. Vol.35. P. 1251–1265.

   134. Mattison J. Ames dwarf mice: a model for delayed aging // Успехи геронтологии 2000. Т. 4. С. 141–146.

   135. Mayersofat M. Pharmacokinetics in the elderly if Environ Health Perspectives Suppl 11. 1994. Vol. 102. P. 119–124.

   136. McCleam G.E. Biomarkers of age and aging. Exp. Gerontol. 1997. Vol. 32. P. 87–94.

   137. Medvedev Z. A. Possible role of repeated nucleotide sequences in DNA in the evolution of life spans of different cells. Nature. 1972. Vol. 237. P. 453–454.

   138. Meichnikoff E. Etudes sur la nature humaine: Essai de philosophie optimiste // Paris: Masson & C-ie, 1903. 399 p.

   139. Men T. Russian mortality trends for 1991–2001: analysis by cause and region // BMJ 2003; 327: 964.

   140. Michelson H., Bolund C., Brandberg Y. Multiple chronic health problems are negatively associated with health related quality of life (HRQOL) irrespective of age // Qual Life Res, 2000; 9: 1093–1104.

   141. Miller M.D., Paradis C.F., Houck P.R., Mazumdar S., Stack J.A., Rifai A.H. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale // Psychiatry Res, 1992; 41:237e48.

   142. Miller M.D., Towers A. Manual of Guidelines for Scoring the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) // Pittsburg, Pa: University of Pittsburgh; 1991.

  143. Miyaishi O., Ando F., Matsuzawa K, et al. Cancer incidence in old age. Mech. Ageing Dev. 2000. Vol. 117. P. 47–55.

   144. Morley A.A. The somatic mutation theory of ageing Mutat. Res. 1995. Vol. 338. P. 19–23.

   145. Munoz E., Rosner F., Friedman R., Sterman H., Goldstein J., Wise L. Financial risk, hospital cost, complications and comorbidities in medical non-complications and comorbidity-stratified diagnosis-related groups // Am J Med, 1988; 84(5):933-9

   146. Nabeshima Y. Klotho: a fundamental regulator of aging. Ageing Res. Rev. 2002. Vol. 1. P. 627–638.

   147. Nickenig G., Harrison, D.G. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis // Circulation 2002; 105: 393–396.

   148. Nordam A., Sorlie V., Forde R. Integrity in the care of elderly people, as narrated by female physicians. Nurs. Ethics. 2 003. Vol. 10(4). Р. 388–403.

   149. Oilman V. M. Development, Aging and Disease. A New Rationale for an Intervention Strategy. Chun Harwood Academic Publ., 1994, 387 p.

   150. Ono Т., Uehara K, KurishitaA. et al. Biological significance of DNA methyla-tion in the aging process. Age & Aging. 1993. Vol. 22. P. 534–543.

   151. Opie L.H. Mechanisms of cardiac contraction and relaxation // Braunwald’s heart disease: a textbook of cardiovascular medicine. Ed. D. Zipes, P. Libby, R.O. Bonow, Braunwald E. 7ed. Pensylvania: Elsevier Saunders, 2005: 457–490.

   152. Papa S., Skuktchev V.P. Reactive oxygen species, mitochondria, apoptosis and aging. Molec. Cell. Biochem. 1997. Vol. 174. P. 305–319.

   153. Perruccio A.V., Katz J.N., Losina E. Health burden in chronic disease: multimorbidity is associ ated with self-rated health more than medical comorbidity alone. J Clin Epidemiol. 2011 Aug 9.

   154. Peto R., Doll R. There is no such thing as aging. Br. J. Med. 1997. Vol. 315. P. 1030–1032.

   155. Pilz S. Elevated plasma free fatty acids predict sudden cardiac death: a 6.85-year follow-up of 3315 patients after coronary angiography // Eur Heart J. 2007; 28(22):2763–2769.

   156. Pincus T., Kallahan L.F. Taking mortality in rheumatoid arthritis seriously: Predictive markers, socioeconomic status and comorbidity // J. Rheumatol, 1996. Vol.13. P. 841–845.

   157. Pletcher S.D., Neuhauser C. Biological aging – Criteria for modelling and a new mechanistic model. Int. J. Modem Physcis. 2000. Vol. 11. P. 525–546.

   158. Qungquht В., Berg S., Lanke J. et al. The effect of genetic factors for longevity: a comparison of identical and fraternal twins in the Swedish Twin Registry. J. Gerontol. A B iol. Sci. Med. Sci. 1998. Vol. 53. P. M441–M446.

   159. Rahman K. Garlic and aging: new isights into an old remedy. Ageing Res. Rev. 2003. Vol. 2. P. 39–56.

   160. Richardson K., Ananou A., Lafortune L., Brayne C., Matthews F.E. Variation over time in the association between polypharmacy and mortality in the older population.Drugs Aging. 2011 Jul 1;28(7):547-60.

   161. Robine J.M., Saito Y., Jagger С. The emergence of exltemely old people: the case of Japan // Exp. Gerontol. 2003. Vol. 38. P. 735–739.

   162. Robins L. How recognizing comorbidities in psychopathology may lead to an improved research nosology // Clinical Psychology: Science and Practice, 1994; 1, 93–95.

   163. Rose M.R. Evolutionary Biology of Aging. N.Y.: Oxfrd Univ. Press, 1991. 221 p.

   164. Rossoni G., Bernareggi M., De Gennaro Colonna V. et al. Lercanidipine protects the heart from low – flow isch emia damage and antagonizes the vasopressor activity of endothelin–1. – J. Cardiovascul. Pharmacol., 1997; 29 (suppl. 1): S. 41–S47.

   165. Rozzini R., Frisoni G.B., Ferrucci L., Barbisoni P., Sabatini T., Ranieri P., Guralnik J.M., Trabucchi M. Geriatric Index of Comorbidity: validation and comparison with other measures of comorbidity // Age Ageing, 2002; Jul;31(4): 277–85.

   166. Rutten B.P.F., Korr H., Steinbusch H.W. M., Schmitz С. The aging brain: L less neurons could be better// Mech. Ageing Dev. 2003. Vol. 124. P. 349–355.

   167. Salisbury C., Johnson L., Purdy S., Valderas J.M., Montgomery A.A. Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract. 2011 Jan; 61(582): e12–21.

   168. Sanderson W.C., Beck A.T., Beck J. Syndrome comorbidity in patients with major depression or dysthymia: Prevalence and temporal relationships // Am J Psychiatry, 1990; 14 7: 10–25–1028.

   169. Schfer I., von Leitner E.C., Schn G., Koller D., Hansen H., Kolonko T., Kaduszkiewicz H., Wegscheider K., Glaeske G., van den Bussche H. Multimorbidity patterns in the elderly: a new approach of disease clustering identifies complex interrelations between chronic conditions. PLoS One. 2010. Dec 29; 5(12): e15941.

   170. Scheidt-Nave C., Richter S., Fuchs J., Kuhlmey A. Challenges to health research for aging populations using the example of «multimorbidity».Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010. May; 53(5): 441-50.

   171. Schellevis F.G., Velden J. vd, Lisdonk E. vd Comorbidity of chronic diseases in general practice // J Clin Epidemiol, 1993; 46: 469–473.

   172. Schofield R.S., Hill J.A. The use of ranolazine in cardiovascular disease // Expert. Opin. Investig. Drugs. – 2002. – Vol. 11, № 1. – P. 117–123.

   173. Schtessinge r D., Van Zant G. Does functional depletion of stem cells drive aging? Mech. Ageing Dev. 2001. Vol. 122.P. 1537–1553.

   174. Schuler J, Dckelmann C, Beindl W, Prinz E, Michalski T, Pichler M. Polypharmacy and inappropriate prescribing in elderly internal-medicine patients in Austria.

   175. Schulz-Aellen M, – F. Aging and Human Longevity. Boston: Birkhauser, 1997. 283 p.

   176. Schulze P. Christian. Myocardial lipid accumulation and lipotoxicity in heart failure. // J Lipid Res 2009; 50: 2137-8.

   177. Schuster E. Polymorbidity and therapy in the aged. Z Arztl Fortbild (Jena). 1977 Jul 15;71(14):673-4.

   178. Schwartz M. W., Woods S. C., Porte D. et al. Central nervous system control of food intake Nature. 2000. Vol. 404. P. 661–671.

   179. Scirica B.M., Morrow D.A., Hod H. Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non – ST-Segment – Elevation Acute Coronary Syndrome. Results From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non – ST-Elevation Acute Coronary Syndrome – Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial // Circulation. October 9, 2007;116:1647–1652.

   180. Shimokawa I., Higanti Y., Utsuyama M. et al. Life span extension by reduction in growth hormone-insulin-like growth factor-1 axis in a transgenic rat model Am. J. Pathol. 2002. Vol. 160. P. 2259–2265.

   181. Siliprandi N., Di Lisa F., Menabo R. Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism // Cardiovasc. Drugs Ther. – 1991. – Vol. 5 (Suppl. 1). – P. 17–24.

   182. Skulachev V. P. Programmes death phenomena: from organelle to organism Ann. N.Y. Acad. Sci. 2O02. Vol. 959. P. 214–237.

   183. SohalR. S. Role of oxida tve stress and protein oxidation in the aging process. Free Radical Biol. Med. 2O02. Vol. 33. P. 37–44.

   184. Sparrow C.P., Burton C.A., Hernandez M. et al. Simvastatin has anti-inflammatory end antiatherosclerotic activities independent of plasma cholesterol lowering //Arterioscler. Thromb Vasc Biol. – 2001. – Vol.21. – Р.115–121.

   185. Starfield B., Lemke K.W., Bernhardt T. Comorbidity: Implications for the Importance of Primary Care in Case Management // Ann Fam Med, 2003; 1(1):8-14

   186. Steger Я W., Bartke A., Cecim M. Premature aging in transgenic mice exressing growth hormone genes//J. Repr. Fertil. Supp]. 1993. Vol.46. P. 61–75.

   187. Stewart S. A., Weinberg R. A. Senescence: does it all happen at the ends? Qn-cogene. 2O02. Vol. 21. P. 627–630.

   188. Stier D.M., Greenfield S., Lubeck D.P., Dukes K.A., Flanders S.C., Henning J.M., Weir J., Kaplan S.H. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer // Urology, 1999; Sep; 54(3):424-9

   189. Strehler B. L, MitdvonA.S. General theory of mortality and aging. Science. 1960. Vol. 132. P.14–21.

   190. Szwed H., Sadowski Z., Pachocki R. et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized,double-blind, multicentre study (TRIMPOL II) TRIMetazidine in POLand // Eur. Heart J. – 2001. – Vol. 22. – P. 2267–2274.

   191. Tacken MA, Opstelten W, Vossen I, Smeele IJ, Calsbeek H, Jacobs JE, Braspenning JC.

   192. Tatti P., Pahor M., Byington R.P., Guarisco R. et al. Outcome result of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial in patient with Hypertension and NIDDM //Diabets Care. 1998, 21 (4): 597–603.

   193. Tautenhahn J, Lobmann R, Koenig B, Halloul Z, Lippert H, Buer ger T.The influence of polymorbidity, revascularization, and wound therapy on the healing of arterial ulceration. Vasc Health Risk Manag. 2008;4(3):683-9.

   194. Taylor AW, Price K, Gill TK, Adams R, Pilkington R, Carrangis N, Shi Z, Wilson D Multimorbidity – not just an older person’s issue. Results from an Australian biomedical study. BMC Public Health. 2010 Nov 22;10:718.

   195. Thatcher A. R., KamistoV., Vaupel J. W. The Force of Mortality at Ages 80 to 120. Odense: Odense Univ Press, 1998.

   196. The Aging Factor in Health and Disease. Workshop Report. New York: International Longevity Center, USA, Ltd., 1999. 24 p.

   197. Thiem U, Theile G, Junius-Walker U, Holt S, Thrmann P, Hinrichs T, Platen P, Diederichs C, Berger K, Hodek JM, Greiner W, Berkemeyer S, Pientka L, Trampisch HJ. Prerequisites for a new health care model for elderly people with multimorbidity: the PRISCUS research consortium. Z Gerontol Geriatr. 2011 Apr;44(2):115-20.

   198. Tiemann AH, Homagk L, Diefenbeck M, Mckley T, Hofmann GO. Preservation of hip prosthesis with local surgical revision and creation of a fistula persistens: an option for palliative treatment of periprosthetic infection in old, polymorbid patients?. Unfallchirurg. 2007 Dec;110(12):1021-9.

   199. Toussaint O., Remade J., DierickJ.-F. etal Approach of evolutionary theories of ageing, stress, senescence-1 ike phenotypes, calorie restriction and hormesis from the view point of far-from-equilibrium thermodynamics Mech. Ageing Dev. 2002. Vol. 123. P. 937–946.

   200. Troen a R. The biology of aging The Maunt Sinai J. Med. 2003. VoL 70. P. 3–22.

   201. Trb CL. Polymorbidity of malignant neoplasms. Osterr Z Erforsch Bekampf Krebskr. 1971;26(3):170-9

   202. Turcani M., Rupp H. Etomoxir improves left ventricular performance of pressure-over loaded rat heart // Circulation. – 1997. – Vol. 96, № 10. – P. 3681–3686.

   203. TynerS. D., VenkatachalatnS., ChotJ. et al. p53 mutant mice that display early ageing-associated plicnotypcs Nature. 2002. Vol. 415. P. 45–53.

   204. Uitz W., O’Neil 8. C, Schebrov S. Europe’s population at a turning point Science. 2003. Vol. 299. P. 1991–1992.

   205. Upschitz D. A. Nutrition, aging and the immunohematopoietic system Clin. Geriatr. Med. 1987. Vol. 3. P. 319–328.

   206. ValteixS., JeannyJ. C, ElsevierS. et al. Expression of human FSB, a gene nested within the coagulation factor VIII gene, produces multiple eye defects and developmental alterations in chimeric and transgenic mice Hum. Genet. 1999. Vol. 8. P. 1291–1301.

   207. Van Bilsen M., Smeets P. J., Gilde A. J., van der Vusse G. J. Metabolic remodelling of the failing heart: the cardiac bum-out syndrome? // Cardiovasc. Res. 2004; 61 (2): 218–226.

   208. Van den Akker M, Buntinx F., Roos S., Knottnerus J.A.. Comorbidity or multimorbidity: what’s in a name? A review of the literature // Eur J Gen Pract, 1996; 2:65-7

   209. Van den Akker M., Buntinx F., Metsemakers J.F., Roos S., Knottnerus J.A. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases // J Clin Epidemiol, 1998; 51:367-375

   210. Van den Bussche H, Koller D, Kolonko T, Hansen H, Wegscheider K, Glaeske G, von Leitner EC, Schfer I, Schn G.Which chronic diseases and disease combinations are specific to multimorbidity in the elderly? Results of a claims data based cross-sectional study in Germany. BMC Public Health. 2011 Feb 14;11:101.

   211. van den Bussche H, Schon G, Kolonko T, Hansen H, Wegscheider K, Glaeske G, Koller D.Patterns of ambulatory medical care utilization in elderly patients with special reference to chronic diseases and multimorbidity – Results from a claims data based observational study in Germany. BMC Geriatr. 2011 Sep 13;11(1):54

   212. Van Oostrom SH, Picavet HS, van Gelder BM, Lemmens LC, Hoeymans N, Verheij RA, Schellevis FG, Baan CA. Multimorbidity and comorbidity in the Dutch population-data from general practices. Ned Tijdschr Geneeskd. 2011;155:A3193.

   213. Van Someren E, J. W., Raymann R. J. E. M., ScherderE. J.A., et al, Orcadian and age-related modulation of thermoreoeption and temperature regulation: mechanisms and functional implications Ageing Res. Rev. 2002. Vol. 1. P. 721–778.

   214. Van Voorhies W. A., Ward S. Genetic and environmental conditios that increase longevity in Caenorhabditis elegans decrease metabolic rate Proc. Natl. Acad. Sci. USA. 1999. Vol. 96. P. 11399–11403.

   215. Van Weel C., Schellevis F.G. Comorbidity and guidelines: conflicting interests // Lance t, 2006; 367:550-551

   216. Vasile E, Totnita K, Brown L F. etai. Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis FASEB J. 2001. Vol. 15. P. 458–466.

   217. Vaupel J. W., Carey J. R., Christensen K. et ai Biodemographic trajectories of longevity Science. 1998. Vol. 280. P. 855–860.

   218. Vaupel J. W., Yashin A. I. Heterogeneity’s rises: some surprising effects of selection on population dynamics //Am. Stat. 1985. Vol.39. P. 176–185.

   219. Veda M. Telomerase in cutaneous carcinogenesis J. Dermatol. Sci. 2000. Vol. 23, Suppl 1. P. S37–S40.

   220. Velculescu V.E, Madden S.L., Zhang L. et al. Analysis of human transcrip-tomes Nat. Genet 1999. Vol. 23. P. 387–388.

   221. Verghese J., Holtzer R., Oh-Park M., Derby C.A., Lip ton R.B., Wang C. Inflammatory markers and gait speed decline in older adults. J Gerontol A Biol Sci Med Sci. 2011 Oct;66(10):1083-9. Epub 2011 Jun 30.

   222. Vijg J. Somatic mutations and aging: a re-evaluation Mutat. Res. 2000. Vol. 447. P. 117–135.

   223. Vijg J., Dolle M. E. T. Large genome rearrangements as a primary cause of aging Mech. Ageing Dev. 2002. Vol. 123. P. 907–915.

   224. Vkraintseva S.V., Yashin A.I. How individual age-associated changes may influence huma morbidity and mortality patterns Mech. Ageing Dev. 2001. Vol. 122. p. 1447–1460.

   225. Vlassara H., Bucala R., Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic and clinical implication for diabetes and aging Lab. Invest. 1994. Vol. 70. P. 138–151.

   226. Vleck С.M., Haussmann M.F., Vieck D. The natural history of telomere: tools for aging animals and exploring the aging process Exp. Gero ntol. 2003. Vol. 38. p. 791–795.

   227. Von Zglinicki T. Oxidative stress shortens telomeres Trends Biochem. Sci. 2002. Vol. 27. P. 339–344.

   228. Walter C. A., Grttbowski D.Т., Street K. A. et at. Analisys and modulation of DNA repair in aging // Mech. Ageing Dev. 1997. Vol. 98. P. 203–222.

   229. Walter L.C., Brand R.J., Counsell S.R., Palmer R.M., Landefeld C.S., Fortinsky R.H., Covinsky K.E. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization // JAMA, 2001; June 20; 285(23): 2987-94.

   230. Wamer H. ft., fngram D., Miller R.A. et al. Program for testing biological interventions to promote health aging Mech. Ageing Dev. 2000. Vol. 155. P. 199–208.

   231. Wang E. Regulation of apoptosis resistance and ontogeny of age-dependent diseases Exp. Gerontol. 1997. Vol. 32. P. 471–484.

   232. Wang J., Hannon G. J., Bea ch D. H. Risky immortalization by telomerase Nature. 2000. Vol. 405. P. 755–756.

   233. Wang P.S., Avorn J., Brookhart M.A. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives // Hypertension, 2005; 46(2):273–279.

   234. Warner H. R., Sierra F. Models of accelerated ageing can be informative about the molecular mechanisms of ageing and/or age-related pathology Mech. Ageing Dev. 2003. Vol. 124. In press.

   235. Walford R. L ITie Immunological Theory of Aging. Copenhagen: Muksgaard, 1969. 338 p.

   236. Wawruch M, Dukat A, Murin J, Wsolova L, Kuzelova M, Macugova A, Wimmer G Jr, Shah R. The effect of selected patient’s characteristics on the choice of antihypertensive medication in the elderly in Slovakia. Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1199-205.

   237. Weindruch R., Kayo Т., Lee C. K. Prolla T.A. Mkroarray profiling of gene expression in aging and its alteration by caloric restriction in mice J. Nutr. 2001. Vol. 13I.P. 918S–923S.

   238. Weismann A. Essays Upon Heredity and Kindred Biological Problems. Oxford: Claderon Press. 1889.